Back to News
Market Impact: 0.35
MacroGenics' Lorigerlimab Shows 25% Response Rate In Clear Cell Gynecologic Cancer
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
MacroGenics reported interim Phase 2 LINNET results for lorigerlimab, with a 25% confirmed objective response rate and a 44% disease control rate in patients with advanced clear cell gynecologic cancer. The early clinical data are positive but interim; the article provides no share-price reaction or additional trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
MGNX0.55
More News
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- Microsoft offers buyouts to nearly 30% of workforce in ongoing AI shift
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- Why is PagSeguro Digital stock plummeting 30% today?
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs